NCT06807437 · SWOG Cancer Research Network
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
What this study is about
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
View original scientific description
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome.
Interventions
PROCEDURE
Biospecimen Collection
Undergo blood sample and pancreas fluid collection
PROCEDURE
Distal Pancreatectomy
Undergo distal pancreatectomy
DRUG
Lanreotide
Given SC
OTHER
Questionnaire Administration
Ancillary studies
OTHER
Saline
Given SC
Primary outcome measures
Incidence of postoperative pancreatic fistula (POPF)
Time frame: Up to 60 days after distal pancreatectomy
POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential
- Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date
- Participants must not have a known history of a prior diagnosis of malabsorption syndrome
- Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization
- Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization
- Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization
- Participants must be ≥ 18 years old
- Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization
- Participants must have a crea
Where
- Birmingham, Alabama
- Daphne, Alabama
- Fairhope, Alabama
- Mobile, Alabama
- Saraland, Alabama
- Gilbert, Arizona
- Duarte, California
- La Jolla, California
- Loma Linda, California
- Los Angeles, California
- San Diego, California
- Newark, Delaware
And 84 more locations — see the full list below.
Collaborators
National Cancer Institute (NCI)
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Mar 31, 2026 · Source of record for eligibility and locations